Download Free Medical IMPACT OF NEXT-GENERATION DNA SEQUENCING AND WHOLE-GENOME ANALYSIS ON PATHOLOGY PRACTICE PowerPoint Presentation

IMPACT OF NEXT-GENERATION DNA SEQUENCING AND WHOLE-GENOME ANALYSIS ON PATHOLOGY PRACTICE PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on Pathology, which is titled "IMPACT OF NEXT-GENERATION DNA SEQUENCING AND WHOLE-GENOME ANALYSIS ON PATHOLOGY PRACTICE", to know about the impact of next-generation dna sequencing and whole-genome analysis on pathology practice.

Tags : Pathology, next-generation dna sequencing, whole-genome analysis, pathology practice

Published on : Aug 06, 2021 | Views : 2222 | Downloads : 5

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

ppt slide no 1 content not found
Slide 2-

IMPACT OF NEXT-GENERATION DNA SEQUENCING AND WHOLE-GENOME ANALYSIS ON PATHOLOGY PRACTICE Wayne W. Grody, M.D., Ph.D. Departments of Pathology & Laboratory Medicine, Pediatrics, and Human Genetics UCLA School of Medicine Director, Diagnostic Molecular Pathology Laboratory and Orphan Disease Testing Center UCLA Medical Center
Slide 3-

ppt slide no 3 content not found
Slide 4-

Genomic (Molecular) Medicine Gene-level diagnostics Gene-level therapeutics
Slide 5-

What is “Personalized Medicine”?
Slide 6-

Personalized Medicine = Molecular Medicine
Slide 7-

“Personalized Medicine” Pharmacogenetics “Companion” Diagnostics Patient-specific therapies
Slide 8-

Is Whole-Genome Sequencing the Ultimate “Personalized Medicine”?
Slide 9-

Somatic vs. Germline Mutation Testing
Slide 10-

Detection of HER2/neu Amplication in Breast Cancer by FISH
Slide 11-

BRCA PEDIGREE
Slide 12-

A BRCA1: 22 coding exons, > 5,500 bp BRCA2: 26 coding exons, > 11,000 bp Sequence Analysis of BRCA1 and BRCA2 Can Find the Needle in the Haystack GGCTTTAAGTATCCAT GGCTTTAAGTATCCAT GGCTTTAAGTATCCAT GGCTTTAAGTATCCAT
Slide 13-

How is Routine Molecular Diagnostics Conducted Now?
Slide 14-

Current Techniques Applied to Molecular Pathology (one gene – one disease) Southern blot Dot blot/Reverse dot blot Polymerase chain reaction SSCP/DGGE RT-PCR DNA sequencing TaqMan, real-time PCR Invader assay In situ hybridization
Slide 15-

New Techniques Coming to Molecular Pathology (all genes – all diseases) Southern blot Dot blot/Reverse dot blot Polymerase chain reaction SSCP/DGGE RT-PCR DNA sequencing TaqMan, real-time PCR Invader assay In situ hybridization Microarray hybridization High-density microarray hybridization Array comparative genomic hybridization Whole-genome sequencing
Slide 16-

Array Comparative Genomic Hybridization (aCGH)
Slide 17-

Whole Genome Data Is Acquired Patient below without any known genetic disease All chromosomes but Y represented
Slide 18-

Xp21 Complex Glycerol Kinase Deficiency Log2-ratio X chromosome 6.66 Mb deletion Start:25274549 End:31940984
Slide 19-

ACMG Recommends Replacing Karyotyping with Chromosomal Microarrays as 'First-Line' Postnatal Test Microarrays should be used instead of G-banded karyotyping as the first test to detect genetic abnormalities in postnatal evaluations, according to the American College of Medical Genetics. September 28, 2010
Slide 20-

CNVs are common in all genomes surveyed … Blue = pathogenic Red = deletion Green = duplication
Slide 21-

And sequence variants are even more common…
Slide 22-

And sequence variants are even more common… Incidentalome
Slide 23-

THE HUMAN GENOME PROJECT Timeline 1985 Exploratory conferences held at UC-Santa Cruz and Santa Fe 1986 Human Genome Initiative announced by DOE 1987 NIH funding commences; 15-year plan formulated 1988 HUGO founded 1989 ELSI established 1990 15-year NIH-DOE project formally begins; $3 billion in funding pledged 1991 Genome Database established 1992 Low-resolution linkage map of entire human genome published 1993 First 5-year plan revised 1994 First 5-year goal achieved one year ahead of schedule 1995 High-resolution physical maps of chromosomes 16 and 19 completed 1996 Yeast genome sequence completed Human genome physical map with 30,000 STS's achieved 1997 NCHGR becomes NHGRI Task Force on Genetic Testing releases report E. coli genome sequence completed High-resolution physical maps of chromosomes X and 7 completed 1998 New 5-year plan announced for project completion by 2003 C. elegans genome sequence completed 1999 First human chromosome (#22) completely sequenced Target date for draft sequence of entire human genome revised from 2001 to 2000
Slide 24-

Sanger Sequencing
Slide 25-

Next-Generation DNA Sequencing
Slide 26-

ppt slide no 26 content not found
Slide 27-

“Next-Generation” Sequencers TenBosch & Grody, J. Molec. Diagn. (2008)
Slide 28-

“Next-Next-” or “Third”-Generation Sequencing Technologies Pacific Biosciences Oxford Nanopore Ion Torrent Others…
Slide 29-

J. Molec. Diagn. 2008; 10:484-492
Slide 30-

Potential Disease Gene Panels for Next-Generation Sequencing Hypertrophic cardiomyopathy Dilated cardiomyopathy Hereditary arrhythmias (channelopathies) Retinitis pigmentosa Albinism Mental retardation Hearing loss
Slide 31-

Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing
Slide 32-

Whole-Genome Sequencing of Tumors
Slide 33-

Whole-Exome Sequencing of Germline DNA
Slide 34-

Should whole-genome/exome sequencing be applied to: Newborn screening? Prenatal diagnosis? Couple screening? Population screening?
Slide 35-

ppt slide no 35 content not found
Slide 36-

NIH Task Force on Genetic Testing
Slide 37-

GINA
Slide 38-

Classes of Novel/Unexpected Sequence Variants Identified by Whole Genome Sequencing Missense variants of uncertain significance in known gene Variants and deleterious mutations in unknown gene(s) Deleterious mutations in unintended target (e.g., BRCA mutations in a baby)
Slide 39-

WGS Represents a Sea-Change in Clinical Laboratory Testing: For the first time, patients will need to choose beforehand what portions of the test results they wish to receive or not receive.
Slide 40-

Informed Consent for Whole Genome Sequencing: Patient Choices Receive all information (CD, DVD?) Receive relevant/targeted information Receive medically actionable information for patient’s age Receive medically actionable information for future Receive medically actionable information for relatives
Slide 41-

Ethical Dilemmas of Whole Genome Sequencing Revelation of “off-target” mutations Many revealed disorders will have no prevention or treatment Revelation of nonpaternity, consanguinity, incest Costs of genetic counseling and follow-up Possible forensic uses of data Data storage and privacy Huge number of novel missense variants
Slide 42-

ppt slide no 42 content not found
Slide 43-

A Little Taste of the Challenge Ahead: Sequencing Experience With BRCA1&2 Complete sequencing of both genes in >150,000 people at Myriad Genetics alone >10,000 mutations and benign or uncertain variants identified [B. Ward, personal communication]
Slide 44-

A Little Taste of the Challenge Ahead: Sequencing Experience With BRCA1&2 Complete sequencing of both genes in >150,000 people at Myriad Genetics alone >10,000 mutations and benign or uncertain variants identified Yet every week, detect 10-20 new missense variants never seen before [B. Ward, personal communication]
Slide 45-

ppt slide no 45 content not found
Slide 46-

ppt slide no 46 content not found
Slide 47-

A Sample of Genetic Testing Patents 5,753,441 BRCA1 5,753,438 Hereditary hemochromatosis 5,741,645 Spinocerebellar ataxia Type 1 5,693,470 Non-polyposis colorectal cancer 5,691,144 CMT-X 5,686,240 Niemann-Pick disease 5,681,699 Ulcer. colitis and Crohn’s disease 5,679,635 Canavan disease 5,670,320 Dystonia, Leber’s optic neuro. 5,658,729 Premature atherosclerosis 5,654,138 Von Hippel-Lindau (VHL) 5,650,282 Williams syndrome 5,650,281 Colorectal cancer 5,645,995 Breast or ovarian cancer 5,645,993 HNLPP 5,639,614 Idiopathic dilated cardiomyopathy 5,639,607 Lead sensitivity 5,565,323 Sporadic Alzheimer disease 5,550,021 Compulsive disorder 5,541,060 Early-onset diabetes mellitus 5,518,880 XSCID 5,508,167 Alzheimer disease 5,506,101 Ototoxic deafness 5,500,343 Compulsive disorder (cocaine) 5,498,521 Retinal degenerative diseases 5,494,794 Alzheimer, Parkinson 5,492,808 Familial colon cancer (FCC) 5,429,923 Hypertrophic cardiomyopathy 5,387,506 Familial dysautonomia 5,374,525 Hypertension 5,306,616 CMT-1A 5,296,349 Myoclonic epilepsy 5,266,459 Gaucher disease 5,210,016 Compulsive disorder (alcohol) 5,045,449 Vascular aneurysms
Slide 48-

“Cease and desist…” Spinocerebellar ataxia (types 1, 2, 3 and 6) Charcot-Marie-Tooth syndrome BRCA1&2 mutations (non-Ashkenazi) Hereditary hemochromatosis Immunoglobulin & TCR gene rearrangements Congenital hearing loss (connexin-26 and -30) MTHFR variants BCR-ABL mutations FLT3 mutations
Slide 49-

Genetic Testing Patents Claim covers the observation of an individual’s genetic makeup at a disease-associated locus when done for diagnostic purposes Includes (bars) all methods of looking at the locus Permits monopolization of a medical practice Permits “ownership” of a disease
Slide 50-

Impact on Healthcare Limited access and noncompetitive pricing Increased healthcare costs Lack of peer review and comparison Hampered quality assurance Potential undetected systematic errors Interference with medical training Restricted opportunity and incentive for test improvements and advancement of the field Missing or masked targets on microarrays and whole-genome sequencing?
Slide 51-

Association for Molecular Pathology et al. v. Myriad Genetics, United States Patent and Trademark Office, et al.
Slide 52-

Key Plaintiffs in the ACLU Suit Association for Molecular Pathology American College of Medical Genetics American Society for Clinical Pathology College of American Pathologists Academic geneticists whose BRCA testing was shut down Breast Cancer Action Network Individual breast cancer patients
Slide 53-

Key Arguments in the ACLU Suit Genes are products of nature, not inventions. It is unconstitutional to patent a person’s individuality. Patients are prevented from seeking a “second opinion”. Gene patents are overly broad. Legal principles bar patenting of laws of nature, products of nature, and abstract ideas. Gene patents violate the First Amendment by inhibiting free speech and access to information.
Slide 54-

Key Arguments of the Defendants The 7 patents deal with “isolated” BRCA genes. “These isolated molecules are man-made chemical compositions, structurally and functionally distinct from any substance found in the human body – indeed, in all of nature.” The method claims involve unique molecular tools such as DNA probes and primers. The inventions made familial breast/ovarian cancer testing practical. “Plaintiffs’ case is nominally directed to Myriad, but actually imperils the entire biotechnology industry – molecular diagnostics, therapeutic drugs, agricultural applications, animal husbandry, etc.” There is no evidence that Myriad has exerted any “adverse legal interest” or damages on the plaintiffs.
Slide 55-

Progress of the ACLU Suit Filed May 2009 in New York Southern District Federal Court Immediate Move to Dismiss rejected Judge Robert Sweet issues Intention to Hear the Case, November 2009 Judge Sweet issues Ruling, March 29, 2010 Myriad appeals the decision to Court of Appeals for the Federal Circuit Depending on that outcome, case could be appealed to the U.S. Supreme Court
Slide 56-

ppt slide no 56 content not found
Slide 57-

Key Arguments in Judge Sweet’s Ruling “DNA represents the physical embodiment of biological information, distinct in its essential characteristics from any other chemical found in nature.” “DNA’s existence in an isolated form alters neither this fundamental quality…nor the information it encodes.” “Therefore, the patents at issue directed to ‘isolated DNA’ containing sequences found in nature are unsustainable as a matter of law and are deemed unpatentable subject matter under 35 U.S.C. §101.”
Slide 58-

ppt slide no 58 content not found
Slide 59-

ppt slide no 59 content not found
Slide 60-

ppt slide no 60 content not found